30 closest matches · ranked by relevance
HIV/AIDS-associated Fatigue
Primary: Change in Fatigue Severity Score (FSS) — -24.7; -16.3; -16.9; -21.6 units on a scale — p=0.15
HIV Infections · Fatigue
Primary: Fatigue Severity Scale(FSS) Outcome — 52.6; 53.1; 25.8; 39.4 units on a scale — p=<0.001
HIV Infection · Fatigue
Primary: Goal Attainment Scale - Modified (GAS): Responder (Score of 3 - Goal Achieved) vs. Non-Responder (Score of 1 or 2 - Goal NOT Achieved) — 29; 9 Participants — p=.602
HIV Infections · Fatigue
Primary: Fatigue Severity Scale (FSS) — 52; 52; 34; 43 units on a scale — p=< 0.001
Hiv · Fatigue · Mobility Limitation
Primary: Change in Physical Function (Part 1) — -15.0; -12.6 Seconds — p=0.35
HIV-1-infection · Sleep Deprivation · Inflammation
Primary: Soluble CD14 — 1290; 1196 ng/mL
Hiv · Insomnia
Primary: Change in hsCRP Levels at 24 Weeks — 2.19; 4.47 mg/L — p=0.607
HIV · Inflammation · Obesity
Primary: Time to Rise From a Chair 10 Times (Modified From the Original Short Physical Performance Battery) — -20; -20; -8; -10 percentage change
Lipodystrophy · HIV Infection
Primary: Change in Insulin Sensitivity From Baseline to Week 12 Post-treatment With Insulin Sensitizing Agent — -0.25; -0.96 mg/kg lean body mass/min
HIV Infections · Lipodystrophy · Metabolic Diseases
Primary: Mitochondrial Function (mtDNA Levels) — 1372 copies per cell
HIV Infection
Primary: Median Change in Visceral Adipose Tissue (VAT) Volume — -4.6 cm^2
HIV
Primary: Interleukin 6 (IL-6) Biological Markers — 2.24; 2.63; 2.53; 2.88 pg/mL
HIV Infection
Primary: Lean Body Mass — 1.8; 0.8 kilograms — p=0.04
Chronic Fatigue Syndrome · Cognitive Impairments
Primary: Change in BRIEF-A — 21.38; 3.36 Scores on a scale — p=.005
HIV Infections · Lipodystrophy · Metabolic Diseases
Primary: Change in Fat mtDNA Content — -169; 321 copies/cell
HIV Infections · Memory
Primary: The Prevalence of Neurocognitive Deficits Among HIV-positive Patients as Defined by the Global Deficit Score Based on the Neuropsychological Testing Battery and to…
HIV Infections · Cardiovascular Disease · Insulin Resistance
Primary: Myocardial Glucose Utilization Rate — 109.6; 106.7; 109.1; 87.2 (nmol glucose/g heart muscle/min
HIV-1
Primary: Phase 1: Forearm Blood Flow (FBF) Response to Acetylcholine (ACh) — 4.6; 4.2; 11.7; 9.9 mL/100 mL tissue/min
Multiple Sclerosis, Relapsing-Remitting
Primary: Fatigue at 28 Weeks — 56.50; 29.00; 55.00; 40.00 score on a scale
HIV Infections
Primary: Change in Mitochondrial Activity — 1250; 1312; 1150; 1125 copies/cell
HIV Infections
Primary: Percent of Liver Fat Pre/Post Challenge With Daily Pioglitazone 45 mg
Neoplasms · Fatigue
Primary: Change From Baseline in Fatigue Scale-Adolescent (FS-A) Score Categorized According to 1-5 Rating Scale of Resource Use and Resource Helpfulness. — -3; -3; -4; -4 units…
HIV Infections
Primary: Neuropsychological Status (i.e., Cognitive Functioning) — 0.008; .484; -.084; -.482 z-score composites of cognitive domains — p=0.001
HIV Infection · Erythrocyte Glutathione Deficiency
Primary: Muscle Glutathione Concentration — 0.5; 2.2 micromol/g.Hb
Sarcoidosis · Fatigue
Primary: Proportion of Participants Recruited — 25; 25 Participants
HIV
Primary: Progression to AIDS or Death in tx naïve Pts With Adv HIV dx in the Four Randomly Assigned Regimens. — 93; 77; 70; 80 participants
HIV
Primary: Aerobic Capacity — 0.15; 0.02 Liters/minute
AIDS-Related-Primary Central Nervous System Lymphoma
Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants
HIV Infections · Lipoatrophy
Primary: Change in Limb Fat (g) From Baseline — 74; 110 grams — p=0.64
HIV Infections · Type 2 Diabetes · Obesity
Primary: Insulin-stimulated Glucose Disposal Rate — 30; 34; 37; 48 µmol glucose/kg FFM/min